Antibodies Elicited by the 2025-2026 Influenza Vaccine.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41774915.
- Also identified by DOI 10.1056/EVIDpha2600007.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
AbstractA new H3N2 variant (named subclade K) possesses several key hemagglutinin substitutions and is circulating widely during the 2025-2026 influenza season. We sought to determine whether the 2025-2026 seasonal influenza vaccine elicits antibodies in humans that recognize this variant. We found that H3N2 subclade K viruses are antigenically advanced; however, the 2025-2026 seasonal influenza vaccine elicited antibodies in many individuals that efficiently recognized these viruses. Thus, the current seasonal influenza vaccine likely will be partially effective at preventing illness associated with H3N2 subclade K virus infections.
Medical subject headings
- Antibodies, Viral
- Influenza A Virus, H3N2 Subtype
- Influenza Vaccines
- Influenza, Human